Apollo Hospitals Enterprise Limited has delivered impressive financial results for Q3FY26, demonstrating strong growth momentum across its integrated healthcare platform. The company announced its unaudited financial results for the three and nine months ended December 31, 2025, showcasing robust performance in all business verticals.

Financial Performance Highlights

The company's consolidated performance for Q3FY26 showed remarkable growth across key metrics:

For the nine-month period ended December 31, 2025, the consolidated results continued to reflect strong performance:

Interim Dividend Declaration

The Board of Directors declared an interim dividend of Rs. 10 per share, representing 200% of the face value of Rs. 5 per share for the financial year 2025-26. The key dates for the dividend payment are:

Segment-wise Performance

Healthcare Services (Hospitals)

The healthcare services division maintained strong growth with revenue of Rs. 31,832 million in Q3FY26 compared to Rs. 27,850 million in Q3FY25, representing 14% YoY growth. EBITDA increased 18% YoY to Rs. 7,898 million with margins at 24.8%. The division operates 8,072 beds across the network with an overall occupancy rate of 67%.

Apollo Health and Lifestyle Limited

The diagnostics and retail healthcare segment showed robust performance with revenue growing 20% YoY to Rs. 4,668 million. EBITDA improved significantly by 39% to Rs. 476 million, with margins expanding to 10.2%.

Apollo HealthCo

The digital healthcare and pharmacy distribution platform delivered strong results with revenue growing 20% YoY to Rs. 28,274 million. EBITDA increased substantially to Rs. 1,279 million compared to Rs. 566 million in the previous year, with margins at 4.5%. The platform added 185 net new stores during the quarter, bringing the total to 7,113 stores.

Operational Milestones

Apollo Hospitals launched a cutting-edge 250-bed quaternary care hospital in Pune, representing the first phase of a planned 400-bed capacity. The facility features advanced surgical robotics, precision oncology, and comprehensive critical care with 100+ ICU beds.

The company continues to lead in transplant care as the world's busiest solid organ transplant program, performing an average of five solid organ transplants daily. The group has completed over 21,000 kidney transplants and more than 5,000 liver transplants, becoming the first hospital group in India to reach this milestone.

Regulatory Impact

The company reported an exceptional item of Rs. 192 million in consolidated results due to the implementation of new Labour Codes notified by the Government of India on November 21, 2025. This one-time impact resulted from increased gratuity and leave liabilities arising from the consolidation of twenty-nine existing labour laws into a unified framework.

Corporate Developments

The Board approved a Composite Scheme of Arrangement involving the demerger of identified business undertakings, primarily representing the omni-channel pharmacy distribution business and digital health platform business. The scheme has received necessary approvals from stock exchanges, and the company has filed an application before the National Company Law Tribunal for final approval.

Apollo Hospitals Enterprise Ltd. has recorded a significant block trade on the National Stock Exchange (NSE), highlighting substantial institutional activity in the healthcare major's shares.

Block Trade Details

The transaction represents a considerable institutional movement in Apollo Hospitals Enterprise Ltd. shares, executed through the NSE's block trading mechanism.

Understanding Block Trades

Block trades are large-volume transactions typically executed by institutional investors, mutual funds, or other large stakeholders. These trades are conducted outside the regular market order book to prevent significant price movements that could occur with such substantial volumes. The execution of block trades often indicates strategic portfolio adjustments by institutional investors or changes in major shareholding patterns.

Market Implications

The substantial value of Rs. 55.83 crores for this block trade underscores the significant institutional interest in Apollo Hospitals Enterprise Ltd. shares. Such transactions are closely monitored by market participants as they can provide insights into institutional sentiment and potential shifts in major shareholding structures within the company.